Trial Profile
A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2019
Price :
$35
*
At a glance
- Drugs Plazomicin (Primary) ; Levofloxacin; Meropenem
- Indications Pyelonephritis; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms EPIC
- Sponsors Achaogen
- 28 Mar 2019 According to an Achaogen media release, the Company has received the Day 120 List of Questions from the European Medicines Agency (EMA) as part of the centralized review process of the MAA for plazomicin.
- 21 Feb 2019 The New England Journal of Medicine has published the results from this trial, as reported in an Achaogen media release.
- 21 Feb 2019 Results published in the Media Release